Disease Landscape and Forecast Insights

This third-time report focuses on the management of diabetic nephropathy (DN) in the United States. The U.S. market for DN drugs is poised to expand owing to the growing size of the DN patient…

The United States accounts for the single largest proportion of the global medical device market, representing approximately 40% of the estimated $400 billion (USD) global market in 2014. Its large…

Diabetic macular edema (DME) is a progressive ophthalmological comorbidity of diabetes that can threaten vision. In DME, fluid and lipids leak from abnormal, weak retinal blood vessels, causing…

Last Updated 2 November 2015 Fueled by multiple label expansions of premium-priced agents and the launch of four novel therapies, the NHL market will experience significant growth over the ten-…

Myelodysplastic syndromes (MDS) consists of a group of hematological stem cell disorders that are heterogeneous in cause and manifestations but share the common features of aberrant hematopoiesis…

Market Access Opportunities for Novel Therapies Targeting Multi-Drug-Resistant Pathogens Hospital-treated Gram-negative infections (GNIs) are becoming increasingly difficult to treat given rising…

Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but…

Last Updated 29 October 2015 The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However…

For the estimated 4.9 million people in the United States who suffer from atrial fibrillation (AF), there are a number of different treatment approaches that can be utilized, each with a wide range…

The past two decades have seen the arrival of revolutionary new biologic therapies for the treatment of numerous diseases, including inflammatory, hematologic, and malignant conditions. The…

Over the last 15 years, we have witnessed a notable shift in oncology drug development activity. Since the U.S. approval of Roche/Genentech’s Herceptin (trastuzumab) in 1998, pharmaceutical…

U.S. Prescriber and Payer Perspective on Current Mainstays, Recent Launches, Late-Stage Products, and the First Generic Competitors The array of disease-modifying therapies (DMTs) approved for the…